Ipsen réalise une croissance remarquable des ventes au cours des neuf premiers mois de 2026 et relève à nouveau ses prévisions pour l’exercice en cours

Ipsen reported 24.6% revenue growth at constant exchange rates for the first nine months of 2026, exceeding expectations and prompting the company to raise its full-year guidance. The group now projects approximately 23.0% revenue growth and 39.0% operating margin for 2026. Growth was driven by its strategic portfolio, particularly Somatuline, alongside progress in its R&D pipeline with advanced-stage assets in oncology, rare diseases, and neurosciences showing blockbuster potential.

10/22/2026, 1:00 AM • GlobeNewswire

Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance

Ipsen reported strong year-to-date sales growth of 24.6% at constant exchange rates for the first nine months of 2026, with the core portfolio achieving 24.2% growth. The company upgraded its full-year 2026 guidance, projecting total sales growth around 23.0% at CER and core operating margin around 39.0%. The company strengthened its late-stage pipeline through acquisitions of Memo Therapeutics and Kartos Therapeutics, adding potravitug and navtemadlin, with multiple blockbuster-potential assets in Oncology, Rare Disease, and Neuroscience.

10/22/2026, 1:00 AM • GlobeNewswire

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

10/19/2026, 1:00 PM • GlobeNewswire

Ipsen - September 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen reported its monthly share capital and voting rights information as of September 30, 2026. The company had 83,814,526 shares composing its share capital, with a gross total of 132,065,045 voting rights and a net total of 130,667,557 voting rights. The report also includes weekly share repurchase program updates for weeks 38 and 39 of 2026.

10/07/2026, 12:00 PM • GlobeNewswire

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.

09/28/2026, 1:51 PM • GlobeNewswire

Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration

Ipsen announces the appointment of Mariette Finet as a board member, effective immediately, replacing Michèle Ollier who resigned on August 1, 2026. Finet brings over 35 years of experience in healthcare, pharmaceuticals, and life sciences. She will also serve on the Product Portfolio Committee. The board remains composed of 14 members with balanced gender representation (7 women, 7 men). Her appointment is subject to shareholder ratification at the next general assembly.

09/18/2026, 3:26 AM • GlobeNewswire

Ipsen appoints Mariette Finet to its Board of Directors

Ipsen announced the appointment of Mariette Finet as a Director to its Board of Directors, effective immediately, succeeding Michèle Ollier who resigned on August 1, 2026. Finet brings over 35 years of healthcare and pharmaceutical experience. She will also join the Board Portfolio Committee. The appointment maintains the board's composition at 14 directors with balanced gender representation (7 women, 7 men) and will be submitted for ratification at the next Annual Shareholders' Meeting.

09/18/2026, 3:26 AM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026

IPSEN conducted share repurchases during the week of September 7-11, 2026, acquiring a total of 35,759 shares at a weighted average price of €158.52 across multiple markets including XETRA, Euronext Paris, and TQEX. No transactions were recorded on September 10, 2026.

09/14/2026, 12:00 PM • GlobeNewswire

GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been admitted to the Euronext Paris CAC Mid 60 and SBF 120 indices effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its profile among institutional investors.

09/11/2026, 1:30 AM • GlobeNewswire

GENFIT va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been included in the Euronext Paris indices CAC Mid 60 and SBF 120, effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its reputation among institutional investors. The company continues to develop therapeutic and diagnostic solutions, including the FDA-approved Iqirvo® for primary biliary cholangitis.

09/11/2026, 1:30 AM • GlobeNewswire

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 35 - 2026

Ipsen has completed its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. This acquisition strengthens Ipsen's late-stage oncology pipeline, representing a strategic expansion of its oncology portfolio.

08/31/2026, 12:00 PM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026

Ipsen has completed its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. This acquisition strengthens Ipsen's late-stage oncology pipeline, representing a strategic expansion of its oncology portfolio.

08/31/2026, 12:00 PM • GlobeNewswire

Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The announcement also includes a corrective statement regarding voting rights disclosure as of June 30, 2026.

07/22/2026, 12:00 PM • GlobeNewswire

Ipsen - Déclaration rectificative corrigeant la déclaration mensuelle du nombre total d'actions et de droits de vote au 30 juin 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The company also published a corrective declaration regarding voting rights and share capital figures as of June 30, 2026.

07/22/2026, 12:00 PM • GlobeNewswire